Patents by Inventor John Salomonsson

John Salomonsson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ORAL FORMULATION OF A THERAPEUTIC COMPOUND
    Publication number: 20260158022
    Abstract: The present invention provides a pharmaceutical tablet formulation of tenapanor that is chemically stable and soluble comprising greater than about 6% w/w of amorphous tenapanor in its bis-HCl form, an acidifying agent, an antioxidant, a disintegrant, a lubricant, a glidant, a filler, and an immediate release coating, wherein the total chloride content of the active ingredient is greater than 5.82% and the particle diameter distribution D50 is from about from about 18 ?m to about 22 ?m.
    Type: Application
    Filed: January 28, 2026
    Publication date: June 11, 2026
    Applicant: ASTRAZENECA AB
    Inventors: Cecilia Gunnarsson, Magnus Swenson, Hanna Matic, John Salomonsson, Eva Karlsson
  • Oral formulation of a therapeutic compound
    Patent number: 12539299
    Abstract: The present invention provides a pharmaceutical tablet formulation of tenapanor that is chemically stable and soluble comprising greater than about 6% w/w of amorphous tenapanor in its bis-HCl form, an acidifying agent, an antioxidant, a disintegrant, a lubricant, a glidant, a filler, and an immediate release coating, wherein the total chloride content of the active ingredient is greater than 5.82% and the particle diameter distribution D50 is from about from about 18 ?m to about 22 ?m.
    Type: Grant
    Filed: December 6, 2021
    Date of Patent: February 3, 2026
    Assignee: ASTRAZENECA AB
    Inventors: Cecilia Gunnarsson, Magnus Swenson, Hanna Matic, John Salomonsson, Eva Karlsson
  • ORAL FORMULATION OF A THERAPEUTIC COMPOUND
    Publication number: 20250255860
    Abstract: The present invention provides a pharmaceutical tablet formulation of tenapanor that is chemically stable and soluble comprising greater than about 6% w/w of amorphous tenapanor in its bis-HCl form, an acidifying agent, an antioxidant, a disintegrant, a lubricant, a glidant, a filler, and an immediate release coating, wherein the total chloride content of the active ingredient is greater than 5.82% and the particle diameter distribution D50 is from about from about 18 ?m to about 22 ?m.
    Type: Application
    Filed: April 11, 2025
    Publication date: August 14, 2025
    Inventors: Cecilia Gunnarsson, Magnus Swenson, Hanna Matic, John Salomonsson, Eva Karlsson
  • ORAL FORMULATION OF A THERAPEUTIC COMPOUND
    Publication number: 20240041858
    Abstract: The present invention provides a pharmaceutical tablet formulation of tenapanor that is chemically stable and soluble comprising greater than about 6% w/w of amorphous tenapanor in its bis-HCl form, an acidifying agent, an antioxidant, a disintegrant, a lubricant, a glidant, a filler, and an immediate release coating, wherein the total chloride content of the active ingredient is greater than 5.82% and the particle diameter distribution D50 is from about from about 18 ?m to about 22 ?m.
    Type: Application
    Filed: December 6, 2021
    Publication date: February 8, 2024
    Inventors: Cecilia Gunnarsson, Magnus Swenson, Hanna Matic, John Salomonsson, Eva Karlsson